ArticleNature communications2025
Divergent transcriptional regulation of redox-homeostasis and permeability modulate rifampicin tolerance and sensitivity in Mycobacterium tuberculosis.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Drug-tolerance in Mycobacterium tuberculosis (Mtb) may delay treatment response while drug hypersusceptibility should improve treatment. We investigate the transcriptional regulation of these states in Mtb using a Transcriptional Regulator Induced Phenotype screen combined with an extended, steady-state rifampicin exposure method. We identify three transcription factors (TFs): Rv1359, Rv2887, and Rv3833, whose induction enhances rifampicin tolerance, and four TFs, Rv1189 (sigI), Rv1846c (blaI), Rv2069 (sigC), and Rv3736, whose induction elicits hypersusceptibility. Inducing the TFs blaI and Rv2887 produces opposite phenotypes due to their divergent regulation of the cydA and icl1, genes that we find to reduce redox stress when overexpressed. Thus, Rv2887 induces icl1 expression which contributes to drug tolerance whereas blaI downregulates cydA, which contributes to drug hypersusceptibility. In contrast, divergent regulation of tgs1 and Rv3083 by the TF Rv3736 results in a convergent hypersusceptible phenotype due to the opposing effects of tgs1 and Rv3083 on Mtb permeability to rifampicin. Our findings demonstrate the complex transcriptional regulation of drug tolerance and hypersusceptibility that cannot be captured by studying the activity of individual effector genes. Induction of TFs that regulate Mtb response to drug exposure may either augment or diminish treatment efficacy. These TFs are thus potential new targets for drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.